甲基纳曲酮对急性胰腺炎严重程度无影响:一项多中心随机对照试验
这项在丹麦4个中心进行的双盲随机安慰剂对照试验纳入105例伴有全身炎症反应综合征的急性胰腺炎成人患者,随机接受5天持续静脉甲基纳曲酮(0.15 mg/kg/d)或安慰剂加标准治疗。主要终点为治疗48小时后胰腺炎活动评分系统评分,两组分别为134.3分与130.5分(差值3.8,95%CI -40.1至47.6;P=0.87),甲基纳曲酮未优于安慰剂。
要点
- 甲基纳曲酮未降低急性胰腺炎48小时胰腺炎活动评分系统评分,与安慰剂无显著差异。
- 疼痛严重程度、疼痛干扰及吗啡等效剂量在两组间均无显著差异。
- 甲基纳曲酮未影响重症疾病风险及死亡率,药物耐受性良好。
核心结论
- 甲基纳曲酮治疗在降低急性胰腺炎严重程度方面未优于安慰剂。
研究设计与样本
- 双盲、随机、安慰剂对照试验,纳入丹麦4个中心的伴有全身炎症反应综合征的急性胰腺炎成人患者。
- 患者随机接受5天持续静脉甲基纳曲酮(0.15 mg/kg/d)或安慰剂加标准治疗。
- 共105例患者(54%男性)随机分配至甲基纳曲酮组(n=51)或安慰剂组(n=54)。
主要发现
- 治疗48小时后胰腺炎活动评分系统评分甲基纳曲酮组为134.3分,安慰剂组为130.5分(差值3.8,95%CI -40.1至47.6;P=0.87)。
- 48小时疼痛严重程度差值0.0(95%CI -0.8至0.9;P=0.94),疼痛干扰差值-0.3(95%CI -1.4至0.8;P=0.55),吗啡等效剂量差值6.5 mg(95%CI -2.1至15.2;P=0.14)。
- 重症疾病风险差值8%(95%CI -11至28;P=0.38),死亡率差值6%(95%CI -1至12;P=0.11)。
- 药物耐受性良好。
关键数值与推荐
- 主要终点为治疗48小时后胰腺炎活动评分系统评分。
- 主要次要结局包括疼痛评分、阿片类药物使用、疾病严重程度和死亡率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Opioids used to manage severe pain in acute pancreatitis (AP) might exacerbate the disease through effects on gastrointestinal and immune functions. Methylnaltrexone, a peripherally acting µ-opioid receptor antagonist, may counteract these effects without changing analgesia. METHODS: This double-blind, randomized, placebo-controlled trial included adult patients with AP and systemic inflammatory response syndrome at 4 Danish centers. Patients were randomized to receive 5 days of continuous intravenous methylnaltrexone (0.15 mg/kg/d) or placebo added to the standard of care. The primary end point was the Pancreatitis Activity Scoring System score after 48 hours of treatment. Main secondary outcomes included pain scores, opioid use, disease severity, and mortality. RESULTS: In total, 105 patients (54% men) were randomized to methylnaltrexone (n = 51) or placebo (n = 54). After 48 hours, the Pancreatitis Activity Scoring System score was 134.3 points in the methylnaltrexone group and 130.5 points in the placebo group (difference 3.8, 95% confidence interval [CI] -40.1 to 47.6; P = 0.87). At 48 hours, we found no differences between the groups in pain severity (0.0, 95% CI -0.8 to 0.9; P = 0.94), pain interference (-0.3, 95% CI -1.4 to 0.8; P = 0.55), and morphine equivalent doses (6.5 mg, 95% CI -2.1 to 15.2; P = 0.14). Methylnaltrexone also did not affect the risk of severe disease (8%, 95% CI -11 to 28; P = 0.38) and mortality (6%, 95% CI -1 to 12; P = 0.11). The medication was well tolerated. DISCUSSION: Methylnaltrexone treatment did not achieve superiority over placebo for reducing the severity of AP.
引用
- Knoph CS, Cook ME, Novovic S, et al. No Effect of Methylnaltrexone on Acute Pancreatitis Severity: A Multicenter Randomized Controlled Trial. Am J Gastroenterol. 2024. PMID: 38916223. doi:10.14309/ajg.0000000000002904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。